Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Juarezic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 3/20 | 0.68 |
| ▸ | HDAC4 known ✓ | P56524 | 3/20 | 0.68 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.68 |
| ▸ | HDAC2 known ✓ | Q92769 | 3/20 | 0.68 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.68 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 3/20 | 0.68 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 2/20 | 0.68 |
| ▸ | HDAC10 known ✓ | Q969S8 | 2/20 | 0.68 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 2/20 | 0.68 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 2/20 | 0.68 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.68 |
| ▸ | MAOB known ✓ | P27338 | 8/20 | 0.61 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.54 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.52 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.50 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.68 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.68 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Juarezic Acid SCHEMBL15119 | 0.98 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL436113 | 0.98 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL474728 | 0.98 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL11522747 | 0.98 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL144680 | 0.98 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL144681 | 0.98 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL3280210 | 0.96 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL30239689 | 0.96 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL2335383 | 0.96 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL5399197 | 0.96 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56122030-A | — | — | None | — | — | JP | disclosed |
| CN-110352226-B | Water-based adhesives composed of dispersed polymer and emulsified silicone polymer | 诺莱克斯股份公司 | 2023-11-07 | — | — | CN | disclosed |
| US-8878169-B2 | Photocurable polymeric materials and related electronic devices | POLYERA CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130200345-A1 | Photocurable Polymeric Materials and Related Electronic Devices | USINVEST LLC | 2013-08-08 | — | — | US | disclosed |
| US-8420698-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120035257-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-20110287535-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-8026280-B2 | For therapy of cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-7902259-B2 | with zinc-binding activities; 5-phenyl-2,4,-pentadienoyl hydroxamic acid; gene expression inhibitor; anticarcinogenic, antitumor, antiprotozoa agent, viricide; hematological disorders, hemoglobinopathies, genetic related metabolic disorders, cystic fibrosis | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
| US-5112924-A | Multilayer fabric, fiber or particle composite of improved heat resistance and high strength | HERCULES INCORPORATED (US) | 1992-05-12 | — | — | US | disclosed |
| US-5096766-A | Prepregs | HERCULES INCORPORATED (US) | 1992-03-17 | — | — | US | disclosed |
| US-4946908-A | DAMAGE TOLERANCE, SHEAR STRENGTH, THERMOCRACKING | HERCULES INCORPORATED (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0363524-A1 | Bismaleimide compositions containing high glass transition temperature and soluble reactive oligomers and composites prepared therefrom | HERCULES INCORPORATED (US) | 1990-04-18 | — | — | EP | disclosed |
| JP-S56122030-A | PHOTOSENSITIVE RESIN COMPOSITION DEVELOPABLE WITH AQUEOUS ALKALI SOLUTION | DAICEL CHEM IND LTD | 1981-09-25 | — | — | JP | disclosed |
| US-4264713-A | COMPRISING LIGHT SENSITIVE POLYMERS OF AN UNSATURATED POLYESTER AND AN ACRYLIC POLYMER WITH UNSATURATED SIDE CHAINS | FUJI PHOTO FILM CO., LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4065430-A | Functional group containing polymer and method of preparing the same | FUJI PHOTO FILM CO., LTD. (JA) | 1977-12-27 | — | — | US | disclosed |
| US-3933885-A | Cinnamylideneacetic acid esters | FUJI PHOTO FILM CO., LTD. (JA) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035257-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 6/4885HDAC4 15/4885HDAC1 1/4885 |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | HDAC3 789/4885HDAC4 618/4885HDAC1 426/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.